Erasca Inc (ERAS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Erasca Inc (ERAS) has a cash flow conversion efficiency ratio of -0.070x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-27.38 Million) by net assets ($393.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ERAS defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Erasca Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Erasca Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Erasca Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Erasca Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Warner Music Group
NASDAQ:WMG
|
0.138x |
|
INTERCORP FIN.SERV. O.N.
F:9IFA
|
0.230x |
|
Beijing Easpring Material Tech
SHE:300073
|
0.022x |
|
Companhia de Saneamento de Minas Gerais
SA:CSMG3
|
0.057x |
|
Wingstop Inc
NASDAQ:WING
|
-0.091x |
|
Forehope Electronic (Ningbo) Co. Ltd. A
SHG:688362
|
N/A |
|
Sensient Technologies Corporation
NYSE:SXT
|
0.037x |
|
Thunder Software Technology Co Ltd
SHE:300496
|
0.017x |
Annual Cash Flow Conversion Efficiency for Erasca Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Erasca Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see ERAS market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $325.17 Million | $-95.45 Million | -0.294x | -13.62% |
| 2024-12-31 | $423.50 Million | $-109.42 Million | -0.258x | +19.16% |
| 2023-12-31 | $316.69 Million | $-101.22 Million | -0.320x | -27.47% |
| 2022-12-31 | $411.85 Million | $-103.26 Million | -0.251x | -43.80% |
| 2021-12-31 | $456.53 Million | $-79.60 Million | -0.174x | -160.80% |
| 2020-12-31 | $-113.98 Million | $-32.69 Million | 0.287x | -62.41% |
| 2019-12-31 | $-13.60 Million | $-10.38 Million | 0.763x | -- |
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid … Read more